Multi-Target-Directed Ligands Targeting Sigma Receptors and the Proteasome—A Holistic Strategy for Cancer Drug Discovery

Cancer cells employ multiple pro-survival strategies, including evasion of apoptosis and escape from immune surveillance. In particular, cancer cells can modulate intracellular calcium homeostasis and exploit sigma receptor (SR) activity to restore calcium balance. Furthermore, the positive correlation between sigma-1 receptor (S1R) and programmed death-ligand 1 (PD-L1) expression levels suggests that S1R may also contribute to immune evasion. Cancer cells maintain proteostasis through enhanced unfolded protein response (UPR) signaling and activation of the ubiquitin–proteasome system (UPS). The proteasome removes misfolded and ubiquitinated proteins, thereby preventing the accumulation of proteotoxic stress, endoplasmic reticulum (ER) stress, and cell death. Collectively, these adaptive mechanisms enable cancer cells to survive, proliferate, and invade, thereby promoting tumor progression. Although proteasome inhibitors (PIs) have been introduced into clinical practice for the treatment of multiple myeloma (MM), their therapeutic use is limited by several drawbacks, including the development of resistance and limited selectivity. Importantly, SRs play a pivotal role in UPR and UPS signaling; therefore, their modulation may compensate for the limitations associated with PI therapy. Consequently, a holistic strategy that simultaneously targets SRs, UPR signaling, and proteasome function may effectively disrupt key pro-survival pathways of cancer cells and represent a promising paradigm for the development of innovative anticancer therapeutics. In the present perspective, we discuss how such multi-target directed ligands (MTDLs) may offer the advantages of simultaneously hitting multiple key pathways and/or their pathogenic cross-talk with a single chemical entity.

Authors

Institutions

Publication Details

Journal
Molecules
Published
2026-11-19
DOI
https://doi.org/10.3390/molecules31224197
Primary Topic
Pharmacological Receptor Mechanisms and Effects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Multi-Target-Directed Ligands Targeting Sigma Receptors and the Proteasome—A Holistic Strategy for Cancer Drug Discovery

Laura Molteni, Simona Collina, Alessio Malacrida, Daniela Rossi et al.
Molecules
Pharmacological Receptor Mechanisms and Effects
article

Multi-Target-Directed Ligands Targeting Sigma Receptors and the Proteasome—A Holistic Strategy for Cancer Drug Discovery

Laura Molteni, Simona Collina, Alessio Malacrida, Daniela Rossi, Mariarosaria Miloso, Pasquale Linciano, Giacomo Rossino, Melania Elettra Vaccari, Sara Salvi
article en

Abstract

Cancer cells employ multiple pro-survival strategies, including evasion of apoptosis and escape from immune surveillance. In particular, cancer cells can modulate intracellular calcium homeostasis and exploit sigma receptor (SR) activity to restore calcium balance. Furthermore, the positive correlation between sigma-1 receptor (S1R) and programmed death-ligand 1 (PD-L1) expression levels suggests that S1R may also contribute to immune evasion. Cancer cells maintain proteostasis through enhanced unfolded protein response (UPR) signaling and activation of the ubiquitin–proteasome system (UPS). The proteasome removes misfolded and ubiquitinated proteins, thereby preventing the accumulation of proteotoxic stress, endoplasmic reticulum (ER) stress, and cell death. Collectively, these adaptive mechanisms enable cancer cells to survive, proliferate, and invade, thereby promoting tumor progression. Although proteasome inhibitors (PIs) have been introduced into clinical practice for the treatment of multiple myeloma (MM), their therapeutic use is limited by several drawbacks, including the development of resistance and limited selectivity. Importantly, SRs play a pivotal role in UPR and UPS signaling; therefore, their modulation may compensate for the limitations associated with PI therapy. Consequently, a holistic strategy that simultaneously targets SRs, UPR signaling, and proteasome function may effectively disrupt key pro-survival pathways of cancer cells and represent a promising paradigm for the development of innovative anticancer therapeutics. In the present perspective, we discuss how such multi-target directed ligands (MTDLs) may offer the advantages of simultaneously hitting multiple key pathways and/or their pathogenic cross-talk with a single chemical entity.

MoleculesVol. 31(22)
University of Pavia (IT), University of Milano-Bicocca (IT)
Pharmacological Receptor Mechanisms and Effects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon